SGB 9768
Alternative Names: SGB-9768Latest Information Update: 06 Jun 2025
At a glance
- Originator SanegeneBio
- Class Amides; Amino sugars; Drug conjugates; Small interfering RNA
- Mechanism of Action Complement C3 expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II IgA nephropathy; Membranoproliferative glomerulonephritis
- Phase I Immunological disorders
Most Recent Events
- 07 Mar 2025 Phase-II clinical trials in IgA nephropathy (Treatment-experienced) in China (SC) (NCT06786338)
- 07 Mar 2025 Phase-II clinical trials in Membranoproliferative glomerulonephritis (Treatment-experienced) in China (SC) (NCT06786338)
- 07 Mar 2025 Efficacy and adverse events data from a phase I trial in Immunological disorders (In volunteers) released by SanegeneBio